NASDAQ:AVRO
AVROBIO Inc Stock News
$1.26
+0.0100 (+0.80%)
At Close: May 08, 2024
AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update
11:00am, Thursday, 06'th Aug 2020
AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the second quarter end
Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results
12:00am, Thursday, 06'th Aug 2020
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to
AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
11:00am, Wednesday, 05'th Aug 2020
AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO,
Head-To-Head Analysis: Avrobio (NASDAQ:AVRO) and Cellectis (NASDAQ:CLLS)
01:36am, Monday, 03'rd Aug 2020
Avrobio (NASDAQ:AVRO) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends,
AVROBIO Sees Hammer Chart Pattern: Time to Buy?
12:23pm, Monday, 27'th Jul 2020
AVROBIO has been struggling lately, but the selling pressure may be coming to an end soon
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:00am, Wednesday, 08'th Jul 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12:00am, Wednesday, 08'th Jul 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today an
AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials
11:00am, Monday, 06'th Jul 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the first patient has been dosed in t
Squarepoint Ops LLC Sells 25,590 Shares of Avrobio Inc (NASDAQ:AVRO)
06:22am, Saturday, 04'th Jul 2020
Squarepoint Ops LLC reduced its position in shares of Avrobio Inc (NASDAQ:AVRO) by 51.0% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund o
Analyzing Avrobio (NASDAQ:AVRO) & Editas Medicine (NASDAQ:EDIT)
02:54am, Tuesday, 30'th Jun 2020
Avrobio (NASDAQ:AVRO) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their ins
AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer
11:00am, Monday, 29'th Jun 2020
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Kim Raineri, as chief m
Here is What Hedge Funds Think About AVROBIO, Inc. (AVRO)
08:16pm, Wednesday, 24'th Jun 2020
In this article you are going to find out whether hedge funds think AVROBIO, Inc. (NASDAQ:AVRO) is a good investment right now. We like to check what the smart money thinks first before doing extensiv
Cowen & Co. Maintains a Buy Rating on IVERIC bio (ISEE) - Markets
12:47pm, Wednesday, 17'th Jun 2020
Cowen & Co. analyst Ken Cacciatore maintained a Buy rating on IVERIC bio (ISEE – Research Report) on June 15
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to...
